Table 2. FGFR4 expression and its correlation to clinicopathological characteristics and response of neoadjuvant chemoradiation treated rectal cancer patients. (a) t-test, (b) Chi square test.
| FGFR4 Expression | p-Value | ||
|---|---|---|---|
| (Negative - Weak)* | (Moderate - Strong)* | ||
| Median age, years | 68.5 (26–79) | 67.5 (34–90) | 0.22(a) |
| Sex, n (%) | |||
| Women | 5 (25) | 7 (30.43) | 0.74(b) |
| Men | 15 (75) | 16 (69.56) | |
| Pre-treatment grading and staging | |||
| Depth of invasion, n (%) | |||
| T1, 2 | 2 (10) | 1 (4.35) | 0.59(b) |
| T3, 4 | 18 (90) | 22 (95.65) | |
| Lymph node metastasis, n (%) | |||
| N0 | 8 (40) | 5 (21.74) | 0.31(b) |
| N1, 2 | 12 (60) | 18 (78.26) | |
| TNM stage, n (%) | |||
| Stage I, II | 8 (40) | 5 (21.74) | 0.31(b) |
| Stage III | 12 (60) | 18 (78.26) | |
| Post-treatment grading and staging | |||
| Depth of invasion, n (%) | |||
| ypTX, 1, 2 | 11 (55) | 10 (43.48) | 0.54(b) |
| ypT3, 4 | 9 (45) | 13 (56.52) | |
| Lymph node metastasis, n (%) | |||
| ypN0 | 16 (80) | 14 (60.86) | 0.2(b) |
| ypN1, 2 | 4 (20) | 9 (39.13) | |
| TNM stage, n (%) | |||
| Stage 0 | 3 (15) | 1 (4.35) | |
| Stage I, II | 13 (65) | 13 (56.52) | 0.25(b) |
| Stage III | 4 (20) | 9 (39.13) | |
| Therapy response** | |||
| Strong response (2–4) | 11 (55) | 5 (21.74) | 0.03(b) |
| Weak or no response (0–1) | 9 (45) | 18 (78.26) | |
*
The classification was done according to the immunoreactive score (IRS): Negative-Weak (0–3), Moderate-High (4–12).
**
Response was determined according to the criteria of Dworak et al. [23].